36-37 - Your moves

Sheffield Teaching Hospitals NHS Foundation Trust has appointed Elaine Coghill as its new Deputy Chief Nurse.
Elaine will join Sheffield Teaching Hospitals from South Tyneside and Sunderland NHS Foundation Trust, where she is currently Deputy Director of Nursing, in April.

Elaine is a highly experienced senior nurse with a nursing career spanning over 28 years. A passionate advocate for patients and the nursing profession, Elaine first qualified as a nurse in Dundee, Scotland, during 1994, but has spent the majority of her nursing career at Newcastle upon Tyne NHS Foundation Trust.

Most recently she has held numerous senior nursing leadership roles, including Deputy Chief Nurse at Northern Lincolnshire and Goole NHS Foundation Trust and Deputy Director of Nursing at South Tyneside and Sunderland NHS Foundation Trust.
The Deputy Chief Nurse role at Sheffield Teaching Hospitals is the second most senior nursing role within the Trust.

LEO Pharma has appointed Kasper Künzel as Interim Vice President and General Manager for LEO Pharma UK and Ireland. Kasper is an established leader within LEO Pharma, having previously been Vice President, IPO Preparedness Office, at LEO Pharma in Denmark.

Kasper brings over 17 years of pharmaceutical experience, previously taking on local and global leadership positions across LEO Pharma in functions including R&D, finance and commercial. Having first joined LEO Pharma in Denmark in a financial function, his previous roles include General Manager in South Korea, Vice President of Corporate Transformation and Director of R&D Business Finance.

Ingenza has welcomed Dr Mark Chadwick to its team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position, acquired over 30 years from a variety of roles within small growth companies, covering the areas of biotechnology, drug discovery and drug development.

Throughout his diverse professional career, Mark has gained experience of building both discovery and development businesses, most notably at BioFocus – now part of Charles River Laboratories – and at pharmaceutical services company Excelsyn.

Mark also led the commercial team at Arcinova for four years, achieving a four-fold growth in sales and customer base prior to the company’s acquisition by Quotient Sciences.

Optibrium has announced the appointment of Steve Yemm as Chief Commercial Officer – the latest in a series of senior-level hires as the company rapidly expands. With over 30 years’ experience in informatics and life sciences, Steve brings an extensive sales and marketing record that will be instrumental to the continued global commercialisation and adoption of Optibrium’s innovative computational and AI drug discovery technologies.

As CCO, Steve will manage the commercial team to drive forward global sales, customer success and marketing activities, as well as working within Optibrium’s executive team to develop commercial strategy.

Steve joins Optibrium from Paradigm4, a company focused on transforming how multidimensional scientific data is integrated, shared and analysed, where he was VP of Sales for Life Sciences and Healthcare.

Opterion Health AG has appointed Peter Reinemer as Chief Executive Officer. Currently Chief Technology Officer, Peter will assume the role of CEO in addition to his current position, replacing Björn Englund, who is leaving the company to take a leadership in the area of dialysis.

Furthermore, Guido Grentzmann, who founded Opterion, has announced his decision to retire as Chief Scientific. Guido will continue to support Opterion as an Advisor. Opterion plans to appoint a Chief Medical Officer in the future.

Adiso Therapeutics, has appointed Srikar Guntaka as its Medical Director. In the newly created role, Srikar will leverage his decade of medical affairs and clinical development experience to help Adiso progress its pipeline of novel, differentiated therapies for the treatment of inflammatory diseases.

Most recently Srikar served as Medical Director, Clinical Development lead at Mirum Pharmaceuticals leading all aspects of global development for multiple indications of volixibat in adults. Prior to Adiso, he was Associate Medical Director, Gastroenterology (US Medical Affairs) at Abbvie where he provided strategic and operational input into core medical affairs activities.

ViCentra BV has announced the appointment of Leo Toole as Chief Financial Officer.
Leo brings a wealth of experience in senior finance roles with more than 25 years’ experience in the medical technology and pharmaceutical sectors. Leo was previously at hVIVO, a UK contract research organisation, specialising in testing infectious and respiratory disease products.

Prior to this, Leo was CFO of Sigmoid Pharma, an Irish specialty pharma company developing drugs for ulcerative colitis, which completed a C$60m financing in 2018. Leo’s other experiences include his roles at BiancaMed and Procter & Gamble across Europe.

Benchling has announced the appointment of its first general manager in EMEA, Bob Burke. It comes at a time when Benchling is accelerating growth in the region.

Bob joins the team at Benchling to build on this local footprint, bringing 25 years of leadership experience across global tech and biotech companies. Most recently, he was at Okta for eight years, where he held senior go-to-market roles focused on customer success, professional services, and the renewals and growth business.

During his tenure, the company grew 50x in revenue, delivered a successful IPO, and completed multiple acquisitions. Prior to Okta, Burke was Global Head of IT for Dynavax Technologies, a biotech company focused on vaccine development.

Publicis Health today announces a trio of senior Creative hires across its UK business. JP Racle joins as Design Director at Langland, Matt Turrell as Creative Director at Digitas Health and Nanda Marth as Creative Director at Saatchi & Saatchi Wellness.

The appointment of JP Racle in the newly created role of Design Director further reinforces the agency’s drive to elevate the creative standard and lead the way for platform creativity in health. JP will run Langland’s integrated design team. He joins from Grey London where he held the position of Head of Digital Content & Experience, having established the digital department from the ground up.

Matt joins Digitas Health as Creative Director where he will lead the agency’s digital-first creative offering. He brings with him a wealth of experience spanning integrated marketing, advertising and design.

Meanwhile, Saatchi & Saatchi Wellness welcomes Nanda as Creative Director. With over 20 years working in healthcare advertising encompassing roles in the US, Brazil and the UK, Nanda not only brings extensive creative leadership experience, but also a passion about how creativity can make a difference.

Scenic Biotech has announced the appointment of Kristof Van Emelen, as Vice President of Drug Discovery. He will be responsible for the development of the company’s pipeline candidates based on genetic modifiers, genes that counteract the effect of a disease-causing gene.

Kristof joins from Ermium Therapeutics, a biotechnology company developing therapies for auto-immune diseases, and brings more than 25 years of big pharma and biotechnology experience.

He has worked with both early-stage biotech and established pharmaceutical companies. Prior to Scenic Biotech, Kristof served as the Head of Medicinal Chemistry for Ermium Therapeutics, a French biotech developing therapeutics to treat auto-immune diseases.

In 2019, he joined as entrepreneur-in-residence for the Flanders Institute for Biotechnology and before that, he served as Chief Operating Officer Product Development at ProDigest. Earlier in his career, he was Scientific Director-Emerging Sciences and Innovation, for The Janssen Pharmaceutical Companies of Johnson & Johnson.

Your Moves

Movers of the Month